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Abstract
Clozapine is the most effective antipsychotic drug for schizophrenia, yet it can cause life-threatening adverse drug
reactions, including myocarditis. The aim of this study was to determine whether schizophrenia patients with
clozapine-induced myocarditis have a genetic predisposition compared with clozapine-tolerant controls. We
measured different types of genetic variation, including genome-wide single-nucleotide polymorphisms (SNPs),
coding variants that alter protein expression, and variable forms of human leucocyte antigen (HLA) genes, alongside
traditional clinical risk factors in 42 cases and 67 controls. We calculated a polygenic risk score (PRS) based on variation
at 96 different genetic sites, to estimate the genetic liability to clozapine-induced myocarditis. Our genome-wide
association analysis identified four SNPs suggestive of increased myocarditis risk (P < 1 × 10−6), with odds ratios
ranging 5.5–13.7. The SNP with the lowest P value was rs74675399 (chr19p13.3, P= 1.21 × 10−7; OR= 6.36), located in
the GNA15 gene, previously associated with heart failure. The HLA-C*07:01 allele was identified as potentially
predisposing to clozapine-induced myocarditis (OR= 2.89, 95% CI: 1.11–7.53), consistent with a previous report of
association of the same allele with clozapine-induced agranulocytosis. Another seven HLA alleles, including HLA-
B*07:02 (OR= 0.25, 95% CI: 0.05–1.2) were found to be putatively protective. Long-read DNA sequencing provided
increased resolution of HLA typing and validated the HLA associations. The PRS explained 66% of liability (P value=
9.7 × 10−5). Combining clinical and genetic factors together increased the proportion of variability accounted for (r2
0.73, P= 9.8 × 10−9). However, due to the limited sample size, individual genetic associations were not statistically
significant after correction for multiple testing. We report novel candidate genetic associations with clozapine-induced
myocarditis, which may have potential clinical utility, but larger cohorts are required for replication.
Introduction
Nearly 50 years after its first commercial use, clozapine
continues to be the most effective antipsychotic drug for
schizophrenia1,2. However, it can cause life-threatening
adverse drug reactions, specifically agranulocytosis3,
gastrointestinal hypomotility4 and myocarditis5. The risk
of agranulocytosis is about 1% and has prompted man-
datory blood monitoring protocols in most countries, and
restriction to prescription as third-line therapy. Together
with concerns about the risk of myocarditis and bowel
obstruction, this has reduced the number of patients
receiving clozapine, despite its demonstrated superior
efficacy.
Myocarditis (inflammation of the heart muscle) occurs
in about 3% of patients commencing clozapine, and can
be fatal5. A protocol has been proposed to monitor
myocarditis concurrently with monitoring agranulocytosis
in the first 4 weeks following initiation of clozapine6. A
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previous case−control analysis, by our group, designed to
identify clinical risk factors for clozapine-induced myo-
carditis, found the reaction was more common with rapid
dose titration, concomitant sodium valproate and
increasing age7. Despite the investigation of a wide range
of host and clinical factors including other concurrent
medications, smoking status, alcohol and illicit drug use,
body-mass index, and duration of psychiatric illness, the
final statistical model accounted for less than 50% of the
risk of myocarditis in individuals commencing clozapine.
Given the wide range of factors considered, we hypothe-
sized that genetic factors could account for a substantial
proportion of the remaining risk.
Clozapine-induced myocarditis is thought to be an
immune-mediated reaction, although the mechanism has
not been fully elucidated. Pharmacogenetic studies of
other immune-mediated adverse drug reactions have
identified alleles in the human leucocyte antigen (HLA)
region with sufficient predictive value for screening prior
to prescribing. Two examples are Stevens−Johnson Syn-
drome and toxic epidermal necrolysis (SJS/TEN) with
carbamazepine in those of South East Asian descent and
hypersensitivity with abacavir8,9.
However, there are notable clinical differences between
the adverse reactions observed with carbamazepine and
abacavir, and myocarditis with clozapine. Rechallenge
after abacavir hypersensitivity produces a rapid and more
severe response than the initial adverse reaction10.
Rechallenge to carbamazepine after SJS/TEN is strictly
contra-indicated. Rechallenge with clozapine after myo-
carditis may lead to a recurrence; but in around 50% of
cases, clozapine has been safely continued long term
without discernible adverse cardiac effects11. This sug-
gests that there may be several predisposing factors
associated with clozapine-induced myocarditis. Indeed,
mild cases of myocarditis have been reported, in which
clozapine has been continued with doses withheld or
temporarily reduced, without any long-term con-
sequences12. This would suggest that any genetic predis-
position to myocarditis is complex, and that at least for
some, risk is modifiable by immunological factors akin to
desensitization, or by environmental factors.
The aim of this study was to investigate the contribution
of genetic factors—common and rare genetic variants
together with HLA gene variants or alleles—to myo-
carditis risk with clozapine. To our knowledge, this is the
first genetic study of clozapine-induced myocarditis.
Methods
Sample description
Cases and controls of the cohort have been described
previously, along with listing of human research ethics
committees from which approvals were obtained6,7,13.
Briefly, cases met clinical and diagnostic criteria for
myocarditis, developing within 45 days of commencing
clozapine13. Controls took clozapine for at least 45 days
with no evidence of myocarditis within this period13.
Those who met the criteria for case or control were
invited via their case manager to provide a blood or saliva
sample for genetic analysis. Samples (stored blood or
tissue) from deceased individuals were obtained with the
consent of the next of kin.
Genome-wide association analyses
Single-nucleotide polymorphisms (SNPs) were geno-
typed using the Human OmniExpressExome-8 v1.0 Bead
Chip (Illumina, Inc.) in DNA samples from 42 cases, and
67 controls. Sample and SNP quality control (QC) and
SNP imputation are described in the Supplementary
Materials. A total of 95 samples (33 clozapine-induced
myocarditis cases, 62 clozapine-tolerant controls) and
587,647 SNPs passed QC. Phasing and imputation were
performed using the Haplotype Reference Consortium
(HRC) panel v1.1 2016 14. Post-imputation SNP QC was
performed (Supplementary Methods) and a final set of
6,822,414 bi-allelic SNPs remained and were used for
association analysis.
Analysis of genotype data was conducted using an
additive logistic regression model in SNPTEST v2.5
adjusting for clinical variables reaching statistical sig-
nificance (P < 0.05) and the first four principal compo-
nents from a genetic relatedness matrix to account for
population stratification. The conventional genome-wide
association study (GWAS) threshold of P < 5 × 10−8 was
regarded as genome-wide significant (Bonferroni-cor-
rected for 1 million SNPs). Since this threshold is con-
servative for small sample sizes, SNPs with P < 1 × 10−5
were considered suggestive of genome-wide significance.
Polygenic risk score analysis
A polygenic risk score (PRS) calculates the aggregate
weighted contribution of multiple low-effect genetic loci
(SNPs) on a given trait or disease outcome. We calculated
a PRS for clozapine-induced myocarditis using a sub-set
of SNPs meeting a more stringent QC threshold, using the
PRSice-2 software15 (Supplementary Materials). We
adjusted for clinical variables and the first four principal
components to control for population stratification. The
R2 value was calculated to estimate the proportion of
explained variance in myocarditis status.
Rare coding variant analyses
Of the SNPs assayed on the Illumina Human
OmniExpressExome-8 v1.0 Bead Chip, 244,331 were
coding (exonic) variants affecting protein expression.
These were used to undertake a limited analysis of rare
coding variants contributing to clozapine-induced myo-
carditis risk (see Supplementary Methods).
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HLA analyses
HLA typing was conducted using short- and long-read
methods. Short-read HLA calls were made using the
Omixon Target HLA Typing software (v1.8.1), following
hybridization capture (SureSelect MHC, Agilent) and
DNA sequencing (2 × 150 bp paired end, Illumina HiSeq).
Long-read, high-resolution HLA typing was performed
using long-range PCR amplification and long-read single
molecule real-time DNA sequencing (Pacific Biosciences
RSII). For this approach, input DNA was amplified using
HLA Class I and II NGSgoAmpX primers (GenDX) and
purified to targeted amplicon sizes (~3–4 kb for HLA-A,
-B and -C). After PCR products were normalized and
pooled, they were subject to size selection, template pre-
paration, barcode multiplexing (eight libraries per pool)
and SMRT sequencing using magnetic bead selection
protocol. Long-read data were processed using the Long
Amplicon Analysis pipeline v2 (Pacific Biosciences).
FASTQ files were imported into the NGSengine
v2.7.0 software (GenDX) for HLA allele calling, SNP
identification and individual base calling.
Short-read DNA sequencing enabled HLA typing at
standard (4-digit) resolution. This detected 29 HLA loci
and 4 non-HLA loci across the major histocompatibility
complex (MHC) (Table S1). Loci with call rates <98%
were excluded (n= 7). Of the remaining 26 loci, 313
alleles were detected (Table S2). Monomorphic alleles (n=
25) and alleles with counts of <1 (n= 86) were excluded.
To minimize co-linearity, only SNPs with correlation
coefficient r2 < 0.8 were included. A final number of 127
HLA and 32 non-HLA alleles in 33 cases and 62 controls
were included for downstream analyses. HLA alleles were
grouped into supertypes (Table S3) according to pub-
lished classifications16,17. The frequency of HLA haplo-
type was explored in publicly available Caucasoid
populations using the ‘haplotype frequency search’ option
on the allele frequency net database.
To evaluate the effect of each individual HLA allele,
HLA supertype and HLA haplotype on clozapine-induced
myocarditis, logistic regression analysis was undertaken
using PLINK software18, assuming a dominant mode of
inheritance, with adjustment for clinical variables with P <
0.05. Correction for multiple testing was undertaken using
Benjamini−Hochberg false discovery rate (FDR)19 in the
genetics package of R (v3.3.1).
Long-read HLA sequencing was performed to improve
accuracy and resolution of the short-read HLA sequen-
cing results, to resolve ambiguities and to generate high-
resolution (eight-digit) HLA calls. Long-read sequencing
detected 11 HLA loci (HLA-A, B, C, DRB1, DRB3, DRB4,
DRB5, DQA1, DQB1, DPA1, and DPB1). HLA loci with
>90% call rate (HLA-A, B, and C) were included in the
concordance check with short-read HLA sequencing data.
Clinical variables and statistical analyses
Statistical associations of clinical variables (sex, smoking,
alcohol abuse, illicit drug use, valproate use, chronic disease,
age, BMI, and cumulative clozapine dose) with clozapine-
induced myocarditis were evaluated using either the Pear-
son’s chi-square test or ANOVA (see Supplementary
Methods). Clinical covariates found to be significantly
associated with clozapine-induced myocarditis were com-
bined with genetic factors using regression models, to cal-
culate the proportion of variability accounted for.
Results
Table 1 provides a summary of the case−control cohort,
clinical variables and genomic measures, as well as numbers
included in each analysis. Exposure to potentially interacting
medication via cytochrome P450 metabolism was minimal
among cases and controls (n= 0–4; Table S4).
Table 1 Cohort description and numbers.
Cases Controls
Number 42 67
Sample type
Fresh blood/saliva/stored blood/tissue 20/11/6/5 61/6/0/0
Age at clozapine initiation
Mean age (years) ± SD 37 ± 12 35 ± 11
Reported ethnicity
European/other/unknown 36/2/4 57/7/3
Outcome fatal 24% (10/42) —
Sex (% male) 71% (30/42) 81% (54/67)
Clinical factors
Smoking—Y/N/Unknown 29/7/6 49/18/0
Alcohol abuse—Y/N/Unknown 10/25/7 9/46/12
Illicit drug use—Y/N/Unknown 8/27/7 12/46/9
Valproate use—Y/N/Unknown 12/26/4 9/58/0
BMI kg/m2 ± SD 31.7 ± 6.8
(n= 30)
27.8 ± 6.5
(n= 54)
Cumulative clozapine dose—days 1–9
Mean (mg) ± SD 751 ± 222
(n= 35)
691 ± 289
(n= 62)
Genetic analyses—QC pass ratea
1. Genome-wide SNP association 79% (33/42) 93% (62/67)
2. Rare variants/gene-level analysis 71% (30/42) 81% (54/67)
3. Targeted short-read HLA typing 93% (33/42) 96% (62/67)
4. Long-read HLA typing/phasing 71% (30/42) 90% (60/67)
aFor reasons for exclusion, see Supplementary methods.
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Genome-wide single-nucleotide polymorphism (SNP)
association
Our analysis found no SNPs reaching genome-wide
significance between cases and controls (Fig. 1). However,
SNPs with suggestive genome-wide significance were
observed in several regions. In particular, there were four
SNPs located on chromosomes 2p21, 6p12.2, 8p21.2, and
19p13.3 (Table 2, Fig. 2) with P < 1 × 10−6. The fre-
quencies of these four variants were at least 20% higher in
cases compared to controls.
The SNP with the lowest P value was rs74675399 located
on chromosome 19p13.3 (P= 1.21 × 10−7; OR= 6.36;
Fig. 2a), within intron 2 of the GNA15 gene. This gene
encodes the G-protein subunit alpha-15 and has previously
been reported in genome-wide association with heart fail-
ure20. The second lowest P value was associated with an
intergenic SNP, rs117188076 (P= 2.98 × 10−7; OR= 13.74;
Fig. 2b), located on chromosome 8p21.2. This variant is
located ~31 kb from the 3′ end of the disintegrin and
metalloproteinase domain-containing protein 7 gene
(ADAM7). The third was also an intergenic SNP, rs2959223
(P= 3.5 × 10−7; OR= 5.55; Fig. 2c), positioned ~8.6 kb
from the 3′ end of transcription factor SIX2 that encodes for
homeobox protein SIX2 on chromosome 2p21. The fourth
was an intronic EFHC1 SNP, rs9463787 (P= 8.08 × 10−7;
OR= 7.67; Fig. 2d) on chromosome 6p12.2. EFHC1
encodes the EF-hand-containing calcium binding protein,
which plays a role in calcium homoeostasis.
Polygenic risk score (PRS)
PRS was calculated using SNP effect sizes (odds ratio)
from the GWAS analysis. Ninety-six SNPs with P < 1 × 10−5
explained 66% of variance in clozapine-induced myocarditis
(PRS P value= 9.7 × 10−5) (Fig. 3).
Exonic variants/gene-based association
A total of 226,140 exonic variants in protein-coding
gene regions genotyped across 30 clozapine-induced
myocarditis cases, and 54 clozapine-tolerant controls
passed quality control for gene-based analysis. No sig-
nificant association was found between the exonic
markers and clozapine-induced myocarditis with regard
to detectable disruption in gene function (Fig. S1).
HLA association
The short-read DNA sequencing enables HLA typing to
two-digit resolution. This identified nine HLA gene var-
iant (allele) associations with clozapine-induced myo-
carditis (Table 3), prior to false discovery rate (FDR)
correction to address type I errors. HLA class I allele
HLA-C*07:01 (OR= 2.89, 95% CI: 1.11–7.53; P= 0.03)
and HLA class II allele HLA-DMB*01:01 (OR= 3.22, 95%
CI: 1.158.97; P= 0.026) were associated with increased
odds for myocarditis.
The other seven HLA alleles were all associated with
decreased frequency of myocarditis (ORs < 1). Two of
these were HLA class I alleles (HLA-B*07:02 and HLA-
C*07:02) and four were HLA class II alleles (HLA-
DQA1*01:02, HLA-DQB1*06:02, HLA-DRA*01:01 and
HLA-DRB1*15:01). One was a non-HLA allele,
MICB*004:01. In addition to allele associations, one
HLA supertype, DR1, exhibited a significant association
with decreased frequency of clozapine-induced myo-
carditis (OR < 1; Table 3). However, none of the allelic
and supertype associations remained significant
after FDR.
Using the allele frequency net database21, HLA-B*07:02,
DQB1*06:02 and DRB1*15:01 were found to be in the
same haplotype group. Among 44 records focusing on the
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Fig. 1 Association of genome-wide genetic variants in clozapine-induced myocarditis cases compared with clozapine-tolerant controls.
The first four principal components and valproate use were included as covariates. a Manhattan plot showing individual −log10 P values plotted
against their genomic position by chromosome. The red line represents the threshold of genome-wide significance (P= 5 × 10−8). The blue line
marks the threshold for suggestive association (P= 1 × 10−5). Blue arrows indicate SNPs with P < 1 × 10−6. b Quantile−quantile (Q−Q) plot of data
shown in Manhattan plot.
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Caucasoid ethnic origin across seven populations, con-
sisting of a total of 1,250,628 individuals, the estimated
occurrence of the HLA-B*07:02, DQB1*06:02 and
DRB1*15:01 haplotypes ranges between 0.01 and 11%. In
our cohort of clozapine-induced myocarditis cases and
controls, the carrier frequency of these three alleles
together was 9.1% and 22.6%, respectively (OR= 0.25,
95% CI: 0.05–1.2; P= 0.083). This suggests that differ-
ences observed in HLA-B*07:02, DQB1*06:02 and
DRB1*15:01 frequencies between cases and controls in
our study are not likely to be due to confounding differ-
ences in population structure.
Long-read HLA typing
Long-read DNA sequencing can span highly variable
HLA gene regions, to enable typing at higher resolution,
to four-digits. Long-read sequencing was used to vali-
date and further resolve HLA calls made by short-read
sequencing in clozapine-induced myocarditis cases and
controls. Among the 96 samples that underwent long-
read HLA DNA sequencing, 90 had short-read HLA
sequencing data available, of which 86 had successful
long-read HLA-B PCR results (Table S5).
All HLA-B*07:02 calls based on short-read data were
identified as HLA-B*07:02:01:01 by long-read analysis.
Eighty samples had successful long-read HLA-C results. All
short-read calls for HLA-C*07:01 and *07:02 were con-
cordant with long-read typing. Carriers of the loci pre-
viously associated with clozapine-induced agranulocytosis22,
HLA-C*07:01 (n= 31), were identified as having HLA-
C*07:01:01:01 (n= 30) and HLA-C*07:01:01:04 (n= 1;
control). The HLA-C*07:02 carriers (n= 31) were identified
as having HLA-C*07:02:01:03 (n= 30) and HLA-
C*07:02:01:01 (n= 1; case). Discordance between HLA
typing calls from short- and long-read DNA sequencing
was observed across five samples (Table S6), but this did not
alter the statistical findings of the short-read HLA analysis.
Regression analysis for myocarditis with clozapine
The univariate associations of clinical variables with
clozapine-induced myocarditis are summarized in Table S7.
We found that the concomitant use of valproate with
clozapine contributes 6.8% to the risk of myocarditis (OR=
3.1, 95% CI: 1.1–8.9; P= 0.03) (Table 4). The addition of
HLA and non-HLA alleles increased the r2 by approxi-
mately 24%. When the top four GWAS SNPs were
included, a further 42% increase in r2 was observed. When
clinical and genetic factors were combined, they explained
a higher proportion of risk (72.6%) compared to clinical
factors alone.
Discussion
This study provides the first evidence, to our knowledge,
that genetic factors contribute to the risk of myocarditisTa
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with clozapine. Although the genetic associations identi-
fied did not reach the conventional statistical threshold
used in human genetics, and require replication in larger
studies, they provide a novel set of candidate genetic loci
for this serious adverse drug reaction, and may be of
potential clinical utility.
A strength of our study is the comprehensive genetic
analyses undertaken using a range of technologies used to
measure different types of genetic variation, including
genome-wide SNP variation, HLA variation and polygenic
risk. Our results have prompted collaborative efforts to
increase sample sizes to improve statistical power to
detect difference, through an international clozapine-
induced myocarditis consortium23.
Several previous genetic studies have been conducted
on clozapine-induced agranulocytosis24. These suggest
agranulocytosis with clozapine may be a heritable trait,
with a complex genetic architecture where numerous
genetic loci contribute, including the HLA genes24, in
combination with clinical factors. Further, a recent
genome-wide association study (GWAS) of neutropenia
in patients taking clozapine identified an association with
HLA-DQB125. Together, these previous studies suggest a
small, but significant role of genetic factors contributing
to the risk of clozapine-induced agranulocytosis and
neutropenia, but no single polymorphism with high pre-
dictive value or current clinical utility. Similarly, the
results of our study suggest that the risk of myocarditis
with clozapine is underpinned by a complex genetic
architecture.
Following either myocarditis or agranulocytosis/neu-
tropenia, the outcome of rechallenge with clozapine may
be favourable11,26. In addition, clozapine has been safely
continued in mild cases of myocarditis12. These observa-
tions suggest that the pathogenesis may not always be a
typical immune-mediated reaction, but one where a
complex combination of genetic and clinical factors lead to
predisposition, and modification of one or more of these,
or a process akin to desensitization, may modulate risk.
From a biological standpoint, we identified genetic risk
loci that provide clues to the underlying aetiology of
myocarditis with clozapine. These loci include four novel
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Fig. 2 Regional plots of SNP regions with associations P < 1 × 10−6. Plots are shown for GNA15 on chromosome 19p13.3 (a), ADAM7 on
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Lacaze et al. Translational Psychiatry           (2020) 10:37 Page 6 of 10
SNPs that approached genome-wide significance, even in
our small sample size. While we found no associations
above the standard statistical threshold for genome-wide
SNP significance (P < 5 × 10−8), there are instances of
SNPs discovered below this threshold being biologically
meaningful, and reaching genome-wide significance sub-
sequently, after larger sample sizes are available27. We
therefore find it reasonable to interpret the biological
consequences and potential clinical utility of the genetic
variation we have identified, albeit with due caution.
The locus with the lowest associated P value was located
within intron 2 of the GNA15 gene and is associated with
six-fold increase in susceptibility to clozapine-induced
myocarditis. This locus has previously been associated
with risk of incident heart failure in adults of European
ancestry20. The GNA15 gene encodes a Ga/q protein that
plays a role in a variety of signalling pathways important
for heart function28. GNA15 sits in a genomic region
(19p13.3) where microdeletions have been linked to
congenital heart disease29. The implicated variant
(rs74675399) sits 132 base pairs upstream from an
enhancer region and 1.7 kilobases downstream of a
promoter flanking region, suggesting it may act as a proxy
for functional genomic elements. Further, clozapine has
high binding affinities to receptors that GNA15 is func-
tionally coupled to, such as 5-HT2 serotonergic, mus-
carinic (M1, M3, M4), alpha-1 adrenergic, and histamine
H1 receptors30. GNA15 is also involved in lymphocyte
and neutrophil activation after pro-inflammatory cytokine
treatment31,32. Even with the caveats of limited sample
size and conservative type 1 error threshold, this provides
a promising candidate locus with biological plausibility,
related to the clinical phenotype observed.
With regards to HLA associations, statistical thresholds
and FDR correction also apply to reduce the possibility of
type I error. We found potential novel HLA associations
with clozapine-induced myocarditis, including the HLA
class I allele HLA-C*07:01 (OR= 2.89, 95% CI: 1.11–7.53;
P= 0.03), previously associated with clozapine-induced
agranulocytosis22. This result suggested an overlapping
role of HLA-C*07:01 in the risk of different clinically sig-
nificant clozapine-induced adverse drug reactions. Inter-
estingly, HLA-C*07:01 has also been associated with the
response to peg-interferon alfa-2b and ribavirin therapy in
Fig. 3 Polygenic risk score analysis using GWAS genetic variants. Risk scores of pruned SNPs at each predetermined significance threshold were
calculated using aggregated sum of weighted risk allele effect sizes. The proportion of variance (R2) explained by the aggregate risk score is shown
on the y-axis.
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hepatitis C33. When we typed C*07:01 patients using high-
resolution, long-read HLA sequencing, we found 30/31
carriers shared the HLA-C*07:01:01:01 sub-type.
We identified seven HLA alleles associated with the
decreased frequency (risk) of clozapine-induced myo-
carditis (ORs < 1), including the HLA-B*07:02 allele (OR=
0.26, 95% CI: 0.07–0.98; P= 0.047). HLA B*07:02 has
been previously associated, by our group, with putative
protective function against carbamazepine hypersensitiv-
ity (Stevens−Johnson syndrome) in Caucasian patients34.
High-resolution typing showed that all HLA-B*07:02
carriers were HLA-B*07:02:01:01 sub-types. Of all patients
with HLA-B calls by long-read sequencing, the HLA-
B*07:02:01:01 allele was present in 18 of 55 controls (33%)
but only 4 of 33 (12%) cases (P= 0.0375).
Together, our results indicate contributions from mul-
tiple genetic loci and HLA alleles to the risk of myo-
carditis with clozapine, suggesting a complex and
polygenic architecture35. To explore this further, we
generated a polygenic risk score using 96 SNPs (P < 1 ×
10−5). This explained 66% of the liability to clozapine-
induced myocarditis (P= 9.7 × 10−5). This was a high
proportion of variability for an exploratory PRS model,
and provides encouraging evidence that use of genetic
information may benefit risk management of clozapine-
induced myocarditis.
In our previous case−control study examining clinical
risk factors for clozapine-induced myocarditis (105 cases,
296 controls), we found that risk of myocarditis in indi-
viduals commencing clozapine was increased by rapid
dose titration, greater patient age and concomitant
sodium valproate use7. In the present study, we confirmed
the association with valproate use (r2 0.07, P= 0.03), and
found that combining clinical and genetic factors together
substantially increased the proportion of variability
accounted for (r2 0.73, P= 9.8 × 10−9). This provided
further evidence that the addition of genetic information
to clinical risk models for clozapine-induced myocarditis
Table 3 Associations of HLA and non-HLA alleles with clozapine-induced myocarditis showing P < 0.05 prior to FDR.
Valproate use was included in the analyses as covariate.
Allele/supertype Cases Controls OR (95% CI) Pa
Carrier Non-carrier Carrier Non-carrier
HLA Class I
HLA-B*07:02 0.10 0.90 0.32 0.68 0.26 (0.07–0.98) 0.047
HLA-C*07:01 0.55 0.45 0.34 0.66 2.89 (1.11–7.53) 0.030a
HLA-C*07:02 0.10 0.90 0.34 0.66 0.25 (0.07–0.92) 0.037
HLA Class II
HLA-DMB*01:01 0.76 0.24 0.52 0.48 3.22 (1.15–8.97) 0.026a
HLA-DQA1*01:02 0.17 0.83 0.45 0.55 0.23 (0.074–0.71) 0.011
HLA-DQB1*06:02 0.10 0.90 0.35 0.65 0.17 (0.045–0.69) 0.012
HLA-DRA*01:01 0.34 0.66 0.68 0.32 0.27 (0.11–0.70) 0.007
HLA-DRB1*15:01 0.10 0.90 0.35 0.65 0.17 (0.045–0.69) 0.012
Non-HLA
MICB*004:01 0.21 0.79 0.48 0.52 0.27 (0.09–0.77) 0.015
HLA supertype
HLA Class II DR1b 0.17 0.83 0.39 0.61 0.28 (0.09–0.89) 0.031
aP values did not remain significant after FDR.
bThe HLA-DRB1 supertype consists of DRB1*15:01, *15:02, *15:03, *15:04, *16:01, and *16:02.
Lines in bold text indicate increased risk of myocarditis.
Table 4 Contribution of clinical and genetic variables to
clozapine-induced myocarditis.
Variable Nagelkerke’s r2 P
Clinical only (valproate use) 0.068 0.029
Clinical+ HLAa 0.307 0.021
Clinical+ HLA+ GWASb 0.726 9.838E–09
aIncluded HLA-B*07:02, HLA-C*07:01, HLA-C*07:02, HLA-DMB*01:01, HLA-
DQA1*01:02, HLADQB1*06:02, HLA-DRA*01:01, HLA-DRB1*15:01, and
MICB*004:01. HLA-DRB1*15:01 was excluded from the model due to redun-
dancy.
bIncluded GWAS top four associations rs2959223, rs9463787, rs117188076,
rs74675399. Bold text indicates statistical signifcance P < 0.001.
Lacaze et al. Translational Psychiatry           (2020) 10:37 Page 8 of 10
may be of potential future clinical utility in risk man-
agement and prevention. However, the genetic associa-
tions identified require validation in larger replication
studies.
There could also be yet undiscovered genetic factors
contributing to myocarditis risk not detected by our
current methods. These include rare, high-effect size
genetic variants detectable by whole-genome or whole-
exome sequencing, large structural variants, or functional
haplotypes in genes relevant to clozapine metabolism (e.g.
CYP1A2).
Limitations
The small sample size of the cohort is the most notable
limitation of this study. We spent a number of years and
considerable resources recruiting even this small number
of patients, encountering a range of challenges. These
included the low population frequency of schizophrenia
(prevalence ~1/100), the restrictions on clozapine pre-
scribing, the reluctance of psychiatrists to prescribe clo-
zapine due to its adverse effects, and the rarity of the drug
reaction amongst patients commencing clozapine (esti-
mated 3/100 patients treated). The stringency of clinical
criteria used to define cases also contributed13. The
sample set was further narrowed by the mental illness of
some potential participants who were not able to be
contacted about contributing a sample, or had cognitive
barriers to participation. Poor DNA quality also con-
tributed to failures for some of the genomic assays used,
further reducing statistical power. In addition, with
regards to measuring rare exonic variants, our analysis
was restricted to only a small sub-set of coding variants
included on the genotyping array used.
Conclusion
We report possible novel genetic associations with
clozapine-induced myocarditis, some of which overlap
with related adverse drug reactions. Our results provide
candidate mechanisms by which clozapine could induce
myocardial inflammation and damage, and identify can-
didate genetic loci that may, in aggregate, be of future
clinical utility for preventing a serious and sometimes fatal
adverse drug reaction. Our results warrant further inves-
tigations for this important clinical phenotype, and vali-
dation in larger studies.
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